Estrogen receptors in human myeloma cells

Cancer Research

Volumn 60, Issue 5, 2000, Pages 1434-1441

  Otsuki, Takemi ^a   Yamada, Osamu ^a   Kurebayashi, Junichi ^a   Moriya, Takuya ^b   Sakaguchi, Haruko ^a   Kunisue, Hironori ^a   Yata, Kenichiro ^a   Uno, Masako ^a   Yawata, Yoshihito ^a   Ueki, Ayako ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b TOHOKU UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; CYTOKINE; ESTROGEN RECEPTOR; FAS ANTIGEN; MESSENGER RNA; TAMOXIFEN;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL GROWTH; CONTROLLED STUDY; GENE TARGETING; HUMAN; HUMAN CELL; MYELOMA CELL; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

ANTINEOPLASTIC AGENTS, HORMONAL; DNA PRIMERS; ESTROGEN ANTAGONISTS; ESTROGENS; HUMANS; MULTIPLE MYELOMA; RECEPTORS, ESTROGEN; RNA, MESSENGER; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 0034162823     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Oken, M. M. Multiple myeloma: prognosis and standard treatment. Cancer Investig., 15: 57-64, 1997.
2. Bjorkstrand, B. Multiple myeloma, high-dose treatment and autologous stem cell transplantation: current status. Med. Oncol., 13: 23-30, 1996.
3. Case, D. C., Jr., Lee, D. J., III, and Clarkson, B. D. Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol. Am. J. Med., 63: 897-903, 1977.
4. Harley, J. B., Pajak, T. F., McIntyre, O. R., Kochwa, S., Cooper, M. R., Coleman, M., and Cuttner, J. Improved survival of increased-risk myeloma patients on combined triple-alkylating-agent therapy: a study of the CALGB. Blood, 54: 13-22, 1979.
5. Salmon, S. E., Haut, A., Bonnet, J. D., Amare, M., Weick, J. K., Durie, B. G., and Dixon, D. O. Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group Study. J. Clin. Oncol., 1: 453-461, 1983.
6. MacLennan, I. C., Kelly, K., Crockson, R. A., Cooper, E. H., Cuzick, J., and Chapman, C. Results of the MRC myelomatosis trials for patients entered since 1980. Hematol. Oncol., 6: 145-158, 1988.
7. Treon, S. P., Teoh, G., Urashima, M., Ogata, A., Chauhan, D., Webb, I. J., and Anderson, K. C. Anti-estrogens induce apoptosis of multiple myeloma cells. Blood, 92: 1749-1757, 1998.
8. Kuiper, G. G., Enmark, E., Pelto-Huikko, M., Nilsson, S., and Gustafsson, J. A. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. USA, 93: 5925-5930, 1996.
9. Mosselman, S., Polman, J., and Dijkema, R. ER β: identification and characterization of a novel human estrogen receptor. FEBS Lett., 392: 49-53, 1996.
10. Kuiper, G. G., and Gustafsson, J. A. The novel estrogen receptor-β subtype: potential role in the cell-and promoter-specific actions of estrogens and anti-estrogens. FEBS Lett., 410: 87-90, 1997.
11. Dotzlaw, H., Leygue, E., Watson, P. H., and Murphy, L. C. Expression of estrogen receptor-β in human breast tumors. J. Clin. Endocrinol. Metab., 82: 2371-2374, 1997.
12. Paech, K., Webb, P., Kuiper, G. G., Nilsson, S., Gustafsson, J., Kushner, P. J., and Scanlan, T. S. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science (Washington DC), 277: 1508-1510, 1997.
13. Vladusic, E. A., Hornby, A. E., Guerra-Vladusic, F. K., and Lupu, R. Expression of estrogen receptor β messenger RNA variant in breast cancer. Cancer Res., 58: 210-214, 1998.
14. Speirs, V., Parkes, A. T., Kerin, M. J., Walton, D. S., Carleton, P. J., Fox, J. N., and Atkin, S. L. Coexpression of estrogen receptor a and β: poor prognostic factors in human breast cancer? Cancer Res., 59: 525-528, 1999.
15. Dotzlaw, H., Leygue, E., Watson, P. H., and Murphy, L. C. Estrogen receptor-β messenger RNA expression in human breast tumor biopsies: relationship to steroid receptor status and regulation by progestins. Cancer Res., 59: 529-532, 1999.
16. Onate, S. A., Tsai, S. Y., Tsai, M. J., and O'Malley, B. W. Sequence and characterization of a coactivator for the steroid hormone receptor superfarmily. Science (Washington DC), 270: 1354-1357, 1995.
17. Halachmi, S., Marden, E., Martin, G., MacKay, H., Abbondanza, C., and Brown, M. Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. Science (Washington DC), 264: 1455-1458, 1994.
18. Voegel, J. J., Heine, M. J., Zechel, C., Chambon, P., and Gronemeyer, M. TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J., 15: 3667-3675, 1996.
19. Hong, H., Kohli, K., Garabedian, M. J., and Stallcup, M. R. GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors. Mol. Cell. Biol., 17: 2735-2744, 1997.
20. Anzick, S. L., Kononen, J., Walker, R. L., Azorsa, D. O., Tanner, M. M., Guan, X. Y., Sauter, G., Kallioniemi, O. P., Trent, J. M., and Meltzer, P. S. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science (Washington DC), 277: 965-968, 1997.
21. Torchia, J., Rose, D. W., Inostroza, J., Kamei, Y., Westin, S., Glass, C. K., and Rosenfeld, M. G. The transcriptional coactivator p/CIP binds CBP and mediates nuclear-receptor function. Nature (Lond.), 387: 677-684, 1997.
22. Li, H., Gomes, P. J., and Chen, J. D. RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2. Proc. Natl. Acad. Sci. USA, 94: 8479-8484, 1997.
23. Chen, H., Lin, R. J., Schiltz, R. L., Chakravarti, D., Nash, A., Nagy, L., Privalsky, M. L., Nakatani, Y., and Evans, R. M. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell, 90: 569-580, 1997.
24. Kim, H. J., Lee, S. K., Na, S. Y., Choi, H. S., and Lee, J. M. Molecular cloning of xSRC-3, a novel transcription coactivator from Xenopus, that is related to AIB1, p/CIP, and TIF2. Mol. Endocrinol., 12: 1038-1047, 1998.
25. Arany, Z., Sellers, W. R., Livingston, D. M., and Eckner, R. E1 A-associated p300 and CREB-associated CBP belong to a conserved family of coactivators. Cell, 77: 799-800, 1994.
26. Yang, X. J., Ogryzko, V. V., Nishikawa, J., Howard, B. H., and Nakatani, Y. A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature (Lond.). 382: 319-324, 1996.
27. Horlein, A. J., Naar, A. M., Heinzel, T., Torchia, J., Gloss, B., Kurokawa, R., Ryan, A., Kamei, Y., Soderstrom, M., Glass, C. K., and Rosenfeld, M. G. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature (Lond.), 377: 397-404, 1995.
28. Chen, J. D., and Evans, R. M. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature (Lond.), 377: 454-457, 1995.
29. Issa, J. P., Zehnbauer, B. A., Civin, C. I., Collector, M. I., Sharkis, S. J., Davidson, N. E., Kaufmann, S. H., and Baylin, S. B. The estrogen receptor CpG island is methylated in most hematopoietic neoplasms. Cancer Res., 56: 973-977, 1996.
30. Kincade, P. W., Medina, K. L., and Smithson, G. Sex hormones as negative regulators of lymphopoiesis. Immunol. Rev., 137: 119-134, 1994.
31. Jilka, R. L., Passeri, G., Girasole, G., Cooper, S., Abrams, J., Broxmeyer, H., and Manolagas, S. C. Estrogen loss upregulates hematopoiesis in the mouse: a mediating role of IL-6. Exp. Hematol, 23: 500-506, 1995.
32. Danel, L., Menouni, M., Cohen, J. H., Magaud, J. P., Lenoir, G., Revillard, J. P., and Saez, S. Distribution of androgen and estrogen receptors among lymphoid and haemopoietic cell lines. Leuk. Res., 9: 1373-1378, 1985.
33. Danel, L., Vincent, C., Rousset, F., Klein, B., Bataille, R., Flacher, M., Durie, B. G., and Revillard, J. P. Estrogen and progesterone receptors in some human myeloma cell lines and murine hybridomas. J. Steroid Biochem., 30: 363-367, 1988.
34. Arceci, R. J. Mechanisms of resistance to therapy and tumor cell survival. Curr. Opin. Hematol., 2: 268-274, 1995.
35. Meyn, R. E., Milas, L., and Stephens, L. C. Apoptosis in tumor biology and therapy. Adv. Exp. Med. Biol., 400B: 657-667, 1997.
36. Bold, R. J., Termuhlen, P. M., and McConkey, D. J. Apoptosis, cancer and cancer therapy. Surg. Oncol., 6: 133-142, 1997.
37. Favrot, M., Coll, J. L., Louis, N., and Negoescu, A. Cell death and cancer: replacement of apoptotic genes and inactivation of death suppressor genes in therapy. Gene Ther., 5. 728-739, 1998.
38. Muschel, R. J., Soto, D. E., McKenna, W. G., and Bernhard, E. J. Radiosensitization and apoptosis. Oncogene, 17: 3359-3363, 1998.
39. Zhivotovsky, B., Joseph, B., and Orrenius, S. Tumor radiosensitivity and apoptosis. Exp. Cell Res., 248: 10-17, 1999.
40. Brown, J. M., and Wouters, B. G. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res., 59: 1391-1399, 1999.
41. Muller, M., Wilder, S., Bannasch, D., Israeli, D., Lehlbach, K., Li-Weber, M., Friedman, S. L., Galle, P. R., Stremmel, W., Oren, M., and Krammer, P. H. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J. Exp. Med., 188: 2033-2045, 1998.
42. Togawa, A., Inoue, N., Miyamoto, K., Hyodo, H., and Namba, M. Establishment and characterization of a human myeloma cell line (KMM-1). Int. J. Cancer, 29: 495-500, 1982.
43. Namba, M., Ohtsuki, T., Mon, M., Togawa, A., Wada, H., Sugihara, T., Yawata, Y., and Kimoto, T. Establishment of five human myeloma cell lines. In Vitro Cell. Dev. Biol., 25: 723-729, 1989.
44. Otsuki, T., Nakazawa, N., Taniwaki, M., Yamada, O., Sakaguchi, H., Wada, H., Yawata, Y., and Ueki, A. Establishment of a new human myeloma cell line, KMS-18, having t(4;14)(p16.3;q32.3) derived from a case phenotypically transformed from Ig A-λ to BJP-λ, and associated with hyperammonemia. Int. J. Oncol., 12: 545-552, 1998.
45. Kurebayashi, J., Kurosumi, M., and Sonoo, H. A new human breast cancer cell line, KPL-1, secretes tumour-associated antigens and grows rapidly in female athymic nude mice. Br. J. Cancer, 71: 845-853, 1995.
46. Kurebayashi, J., Kurosumi, M., and Sonoo, H. A new human breast cancer cell line, KPL-3C, secretes parathyroid hormone-related protein and produces tumours associated with microcalcifications in nude mice. Br. J. Cancer, 74: 200-207, 1996.
47. Kurebayashi, J., Otsuki, T., Tang, C. K., Kurosumi, M., Yamamoto, S., Tanaka, K., Mochizuki, M., Nakamura, H., and Sonoo, H. Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6. Br. J. Cancer, 79: 707-717, 1999.
48. Coezy, E., Borgna, J. L., and Rochefort, H. Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res., 42: 317-323, 1982.
49. Clarke, R., Skaar, T., Baumann, K., Leonessa, F., James, M., Lippman, J., Thompson, E. W., Freter, C., and Brunner, N. Hormonal carcinogenesis in breast cancer: cellular and molecular studies of malignant progression. Breast Cancer Res. Treat., 31: 237-248, 1994.
50. Kurebayashi, J., Otsuki, T., Kunisue, H., Tanaka, K., Yamamoto, S., and Sonoo, H. Expression levels of estrogen receptor-α, -β, co-activators and co-repressors in breast cancer. Clin. Cancer Res., 6: 512-518, 2000.
51. Otsuki, T., Tomokuni, A., Sakaguchi, H., Aikoh, T., Matsuki, T., Isozaki, Y., Hyodoh, F., Kusaka, M., Kita, S., and Ueki, A. Overexpression of decoy receptor 3 (DcR3) gene in peripheral blood mononuclear cells derived from silicosis cases. Clin. Exp. Immunol., 119: 323-327, 2000.
52. Katzenellenbogen, B. S. Estrogen receptors: bioactivities and interactions with cell signaling pathways. Biol. Reprod., 54: 287-293, 1996.
53. Smith, C. L. Cross-talk between peptide growth factor and estrogen receptor signaling pathways. Biol. Reprod., 58: 627-632, 1998.
54. Shyamala, G., Schneider, W., and Guiot, M. C. Estrogen dependent regulation of estrogen receptor gene expression in normal mammary gland and its relationship to estrogenic sensitivity. Receptor, 2: 121-128, 1992.
55. Mon, K., Fujii, R., Kida, N., Takahashi, H., Ohkubo, S., Fujino, M., Ohta, M., and Hayashi, K. Complete primary structure of the human estrogen-responsive gene (pS2) product. J. Biochem. (Tokyo), 107: 73-76, 1990.
56. Otsuki, T., Yamada, O., Sakaguchi, H., Tomokuni, A., Wada, H., Yawata, Y., and Ueki, A. Human myeloma cell apoptosis induced by interferon-α. Br. J. Haematol., 103: 518-529, 1998.
57. Klein, B., Lu, Z. Y., Gu, Z. J., Costes, V., Jourdan, M., and Rossi, J. F. Interleukin-10 and Gp130 cytokines in human multiple myeloma. Leuk. Lymphoma, 34: 63-70, 1999.
58. Nishiura, T., Karasuno, T., Yoshida, H., Nakao, H., Ogawa, M., Horkawa, Y., Yoshimura, M., Okajima, Y., Kanakura, Y., Kanayama, Y., and Matsuzawa, Y. Functional role of cation-independent mannose 6-phosphate/insulin-like growth factor II receptor in cell adhesion and proliferation of a human myeloma cell line OPM-2. Blood, 88: 3546-3554, 1996.
59. Xu, F., Gardner, A., Tu, Y., Michl, P., Prager, D., and Lichtenstein, A. Multiple myeloma cells are protected against dexamethasone-induced apoptosis by insulin-like growth factors. Br. J. Haematol., 97: 429-440, 1997.